Pila Pharma AB (publ)

Stockholm Stock Exchange PILA.ST

Pila Pharma AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 74.15

Pila Pharma AB (publ) Price to Sales Ratio (P/S) is 74.15 on January 14, 2025, a 205.77% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Pila Pharma AB (publ) 52-week high Price to Sales Ratio (P/S) is 133.96 on July 12, 2024, which is 80.66% above the current Price to Sales Ratio (P/S).
Pila Pharma AB (publ) 52-week low Price to Sales Ratio (P/S) is 18.01 on March 25, 2024, which is -75.71% below the current Price to Sales Ratio (P/S).
Pila Pharma AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 60.87.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: PILA.ST

Pila Pharma AB (publ)

CEO	Mr. Gustav Hanghoj Gram
IPO Date	July 15, 2021
Location	Sweden
Headquarters	VAestergatan 1
Employees	1
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

Key trends

Past 5 years